3 ms·

> Your last point is also hysterical because yes, the research needs massive investment, the state provides it, and then allows private companies to run off wit

> Your last point is also hysterical because yes, the research needs massive investment, the state provides it, and then allows private companies to run off with it A research is only the beginning. It usually takes many years and lot of investment to bring a drug to the market. There is also high risk that none of the investment will be recouped. That’s the role that private companies can do well. They don’t just “run off with it”. ASML, for example, benefits heavily from EUV research done in the US with public fund. Yet you can’t say they ran off with it. They invested heavily, and it took them many years to perfect the technology.

bugglebeetle 3y ago
Refer, again, to the example of Cuba’s COVID vaccine.
- signatoremo 3y ago
  Check out the list of drugs that Moderna has in the pipeline: https://www.modernatx.com/research/product-pipeline https://www.modernatx.com/research/product-pipeline Almost all of them are still long way to go before becoming commercial products, if at all. Does it look like they run off with it as you asserted? Or do they have to shoulder the development cost and risk? One of the drugs is of course their COVID vaccine which is a home run. It’s the potential of such windfall that makes them willing to bet on all of the other drugs in the pipeline. You cited Cuba’s COVID vaccine. How many other drugs do they have in pipeline? Right, not so many compared to all of the drugs developed by private money. Ask yourself, with regard to their COVID vaccine, how extensive was the testing? can they scale the production? how widely can they distribute the vaccine?
  - bugglebeetle 3y ago
    Cuba has a fairly large biomedical sector and export industry, despite being under crushing sanctions. It’s absurd to ask about the scale of their development relative to private industry in the US because it’s impossible for them to even gain access to the same raw materials. But that’s also entirely beside the point because the discussion was about whether we need to allow Moderna to rake in billions off public investment in basic research and IP rentiering in order to make COVID vaccines possible. The example of the Cuban vaccine disproves this, but all the pharma apologists of course prefer to talk circles around this point instead of addressing it.

bugglebeetle 3y ago

Refer, again, to the example of Cuba’s COVID vaccine.

signatoremo 3y ago
Check out the list of drugs that Moderna has in the pipeline: https://www.modernatx.com/research/product-pipeline https://www.modernatx.com/research/product-pipeline Almost all of them are still long way to go before becoming commercial products, if at all. Does it look like they run off with it as you asserted? Or do they have to shoulder the development cost and risk? One of the drugs is of course their COVID vaccine which is a home run. It’s the potential of such windfall that makes them willing to bet on all of the other drugs in the pipeline. You cited Cuba’s COVID vaccine. How many other drugs do they have in pipeline? Right, not so many compared to all of the drugs developed by private money. Ask yourself, with regard to their COVID vaccine, how extensive was the testing? can they scale the production? how widely can they distribute the vaccine?
- bugglebeetle 3y ago
  Cuba has a fairly large biomedical sector and export industry, despite being under crushing sanctions. It’s absurd to ask about the scale of their development relative to private industry in the US because it’s impossible for them to even gain access to the same raw materials. But that’s also entirely beside the point because the discussion was about whether we need to allow Moderna to rake in billions off public investment in basic research and IP rentiering in order to make COVID vaccines possible. The example of the Cuban vaccine disproves this, but all the pharma apologists of course prefer to talk circles around this point instead of addressing it.